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Many faces of DAMPs in cancer therapy
O Krysko1, T Løve Aaes2,3, C Bachert1, P Vandenabeele*,2,3,4 and DV Krysko*,2,3,4
A new concept of immunogenic cell death (ICD) has recently been proposed. The immunogenic characteristics of this cell death
mode are mediated mainly by molecules called ‘damage-associated molecular patterns’ (DAMPs), most of which are recognized
by pattern recognition receptors. Some DAMPs are actively emitted by cells undergoing ICD (e.g. calreticulin (CRT) and
adenosine triphosphate (ATP)), whereas others are emitted passively (e.g. high-mobility group box 1 protein (HMGB1)). Recent
studies have demonstrated that these DAMPs play a beneficial role in anti-cancer therapy by interacting with the immune system.
The molecular pathways involved in translocation of CRT to the cell surface and secretion of ATP from tumor cells undergoing
ICD are being elucidated. However, it has also been shown that the same DAMPs could contribute to progression of cancer
and promote resistance to anticancer treatments. In this review, we will critically evaluate the beneficial and detrimental roles of
DAMPs in cancer therapy, focusing mainly on CRT, ATP and HMGB1.
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Facts
 Immunogenic cell death (ICD) is characterized by secre-
tion, release or surface exposure of damage-associated
molecular patterns (DAMPs).
 Surface-exposed calreticulin (CRT), actively secreted
adenosine triphosphate (ATP) and passively released
high-mobility group box 1 protein (HMGB1), the key
DAMPs of ICD, play a beneficial role in anti-cancer therapy
by activating the immune system.
 Depending on the cell death inducer, a specific signaling
pathway is activated, leading to CRT surface exposure and
ATP secretion.
 Of note, that different conditions of ATP (e.g. different
extracellular concentrations) and HMGB1 (e.g. different
redox states) could have different biological effects con-
tributing to tumor metastasis and tumor progression.
Open Questions
 Which redox state of HMGB1 is responsible for the pro- and
anti-tumorigenic activities?
 What determines the difference between DAMPs that drive
cancer progression and those that inhibit tumor growth?
 Large-scale clinical studies are necessary to determine the
prognostic value of ICD associated with DAMP emission in
different types of cancers.
More than 20 years ago the ‘danger theory’ was proposed.
This theory explains why potent immune responses are
elicited against tissue transplants, ischemia-related injuries,
tumors and autoimmune diseases, none of which involve
microbial components.1 It states that the immune system can
distinguish between dangerous and innocuous endogenous
signals. In response to trauma, ischemia and other types of
tissue and cell damage, and death, certain molecules that
perform predominantly non-immunological functions inside
the cell are released or secreted from damaged or dead/dying
cells or exposed on their surface, thereby initiating an immune
response in the absence of infection. These immunostimula-
tory molecules were later named damage-associated
molecular patterns (DAMPs). They can be derived from
any compartment of the cell (Figure 1).2,3 The modification
of DAMPs by proteolysis and oxidation, which often
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accompanies cell death, modulates their immunostimulatory
potential.4,5 Most of the DAMPs that resemble pathogen-
associated molecular patterns (PAMPs) stimulate the
immune system through a broad family of membrane-bound
or cytoplasmic pattern-recognition receptors, which include
Toll-like receptors (TLRs), NOD-like receptors and RIG-I-like
receptors.2,3,6–8
In the past several years it has been shown that DAMPs can
be emitted actively (calreticulin (CRT) and adenosine
triphosphate (ATP)) or passively (high-mobility group box 1
protein (HMGB1)) from tumor cells undergoing immunogenic
apoptosis, that is, immunogenic cell death (ICD). It has been
shown that ICD induction is stressor-dependent9 and requires
reactive oxygen species (ROS)-based endoplasmic reticulum
(ER) stress.10,11 Therefore ICD inducers are classified
as Type I (e.g. anthracyclines, mitoxantrone, oxaliplatin,
cyclophosphamide, UVC and g-radiation) or Type II (e.g.
hypericin-based photodynamic therapy (PDT)).12 Type I ICD
inducers trigger ICD through targets that are not associated
with the ER but stimulate ICD-associated immunogenicity
through secondary or ‘collateral’ ER stress effects. In contrast,
Type II ICD inducers selectively target the ER to induce cell
death and ICD-associated immunogenicity in an ER-focused
manner. It has been shown that DAMPs have a beneficial role
in experimental models of anti-cancer therapy because of
their interaction with the immune system. Tumor cells killed
in vitro and implanted subcutaneously into syngenic immu-
nocompetent mice canmediate an ‘anti-cancer vaccine effect’
in the absence of any adjuvants or immunostimulatory
substances.11,13,14 In this experimental model, considerable
proportions of mice inoculated in this way are protected
against subsequent re-challenge with live cancer cells and
develop fewer tumors at the re-challenge site. It has been
shown that surface exposure of CRT, secretion of ATP and
passive release of HMGB1 are required for the activation of
potent anti-cancer immunity.11,13,14 However, in the sponta-
neous mammary murine tumor model it has been shown that
the adaptive immune system is not needed for the therapeutic
efficacy of immunogenic chemotherapeutics such as oxali-
platin and doxorubicin.15 Also, recent studies have shown that
some of these DAMPs (e.g. HMGB1) contribute to the
progression of cancer16 and promote resistance to anti-
cancer treatments.17–21 In this review, we will discuss the
beneficial and detrimental roles of DAMPs in cancer therapy,
including the mechanisms of emission of three vital DAMPs,
namely, surface-exposed CRT, secreted ATP and released
HMGB1.
Role of CRT Surface Exposure During ICD in Cancer
Treatment
CRT is a soluble protein in the lumen of the ER, traditionally
regarded as a Ca2þ homeostasis regulator and an ER
chaperone.22 It is involved in several functions inside and
outside the ER, such as regulation of chaperone activity and
Ca2þ homeostasis, assembly of the major histocompatibility
complex class I molecules, and cellular proliferation and
migration.3,23 It has been shown that certain anti-cancer
modalities induce ICD of tumor cells characterized by surface
exposure of CRT before signs of apoptosis (i.e. exposure of
PS).13 Surface-exposed CRT facilitates tumor antigen pre-
sentation and tumor-specific cytotoxic T-lymphocyte
responses. It has been shown that the exposure of CRT on
the cell surface of cancer cells in response to anthracyclines is
dependent on the ER-stress response24 associated with
ROS production.10,25 Several CRT translocation pathways
have been described. The first pathway described is induced
by anthracyclines and is dependent on PERK-mediated
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Figure 1 DAMPs are derived from different compartments of the cells. For example, they can come from mitochondria (DNA, formyl peptides and ATP), nucleus (HMGB1,
high-mobility group box 1 protein; HMGN1, high mobility group nucleosome binding protein 1; histones), ER (calreticulin and ATP) and cytoplasm (ATP and F-actin)2,74,78
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eukaryotic initiation factor 2a-phosphorylation (eIF2a-P), the
secretory pathway and caspase-8-mediated BCAP31
(BAP31)-dependent activation of BAX or BAK proteins.10
However, recently it has been shown that only PERK,
BAX or BAK and the secretory pathway are required for the
surface translocation of CRT in response to hypericin-
photodynamic therapy (PDT).11 In this case, PERK governed
the trafficking of ecto-CRT by regulating the proximal
secretory pathway.11 eIF2a-phosphorylation and caspase-8
signaling were not required for CRT exposure. The pathway
that is used for CRT translocation strongly depends on the
apoptotic stage during which the exposure takes
place.12 Indeed, either knockdown of CRT or vaccination of
mice with cells deficient in any of the proteins required for CRT
exposure reduced the immunogenicity of the cancer cells.11,13
All these data indicate that cancer cells undergoing
ICD induce protective immunity against the viable
cancer cells in the prophylactic anti-cancer vaccination
models in mice.
But what about the role of surface-exposed CRT in anti-
cancer treatment in humans, where the situation could be
different? It has been shown that anthracycline treatment of
human prostate cancer, ovarian cancer and acute lympho-
blastic leukemia cell lines (and also primary tumor cells)
induces key features of ICD (such as CRT exposure and
release of HMGB1) like those in mouse cancer cells.26 The
authors showed that the cells undergoing ICD induced
maturation of dentritic cells (DCs), which stimulated tumor-
specific IFN-g-producing T cells. Another study showed that
CRT exposure correlates with the therapeutic benefit of
vaccination with DCs pulsed with primary lymphoma cells
undergoing ICD (triggered by heat shock, g-irradiation and
ultraviolet C-light) in indolent non-Hodgkin’s lymphoma
patients.27 However, leukemic cells isolated from some
patients with acute myeloid leukemia (AML) exhibited CRT
surface exposure regardless of chemotherapy, and this
exposure was not modulated by in vivo chemotherapy,
including anthracyclines.28 The authors also detected high
levels of exposed CRT on malignant myeloblasts, and the
level was positively correlated with the ability of autologous
T cells to secrete IFN-g in response to DCs, suggesting that
the presence of CRT on the surface of leukemia cells
facilitates cellular anti-cancer immune responses in AML
patients. Apoptotic AML cells collected during in vivo therapy
with all-trans retinoic acid showed increased exposure of CRT
during spontaneous in vitro apoptosis, suggesting that in vivo
pharmacotherapy can induce ICD.29 But the authors detected
a wide variation of the level of CRT exposure between
patients, which probably depends on individual patient
characteristics.29 It has also been shown that serum CRT
levels are significantly higher in lung cancer patients after
chemotherapy compared to untreated patients.30 However, in
this study correlation of CRT with efficacy of anti-cancer
therapy was not examined. In conclusion, there is still no
conclusive clinical data on the association between CRT
surface exposure and favorable outcome of anti-cancer
therapy. Large-scale studies are needed to determine the
prognostic value of immunogenic cell death associated with
surface translocation/secretion of CRT in patients suffering
from different types of cancers.
Role of Extracellular Emission of ATP During ICD in
Cancer Treatment
During the past few years, it has become clear that
cells undergoing different types of cell death passively release
or actively secrete ATP.2,11,31–33 Several mechanisms of
ATP secretion in dying/dead/stressed cells have been
reported.11,34–36 Like the exposure of CRT, the mechanism
for ATP secretion in ICD strongly depends on the apoptotic
stage and the type of stress or cell death stimulus that induces
ICD.12 In PDT-induced ICD, ATP was actively secreted from
cells during the pre-apoptotic stage, and this secretion was
dependent on the classical as well as the PERK-regulated
secretory pathway and PI3K-dependent exocytosis, but it was
independent of BAX/BAK.11
It has been shown that ATP released from dying tumor
cells is required for the immune response to cancer cells.37
Cancer cells undergoing ICD in response to anthracycline
secrete ATP in an autophagy-dependent manner.32,35,36
The authors showed that suppression of autophagy inhibited
the early apoptotic secretion of ATP from dying cells killed by
chemotherapeutics and compromised the tumor-specific
immune response in vivo (Figure 2).32,35,36 Although all these
data suggest that ATP functions as an efficient adjuvant in
anti-cancer treatment, no published clinical trials have
confirmed this yet.
It is important to note that extracellular ATP, besides acting
as a DAMP that stimulates anti-tumor immune responses, can
also function as a ‘find me’ signal facilitating rapid attraction of
antigen-presenting cells to sites of extensive apoptotic cell
death.31 It has been reported that extracellular ATP is involved
in the regulation of cell migration of DCs38–40 and also prostate
cancer cells.41 Thus, by stimulating cell migration (e.g. cancer
cells), extracellular ATP could also modulate cancer
invasion and metastasis and thereby have a negative effect
on anti-cancer treatment. This possibility has to be tested in
experimental cancer models.
Extracellular ATP can also stimulate cell proliferation42 and
it could be a source of immunosuppressive agents such as
adenosine.12 Pro-inflammatory ATP can be hydrolyzed to
immunosuppressive adenosine,43,44 which could lead to
immune suppression and development of a tumor-promoting
microenvironment that reduces the efficacy of anti-tumor
immune responses (Figure 2).44–46 Another interesting topic
for future research is to understand the factors or conditions
that determine the biological responses of cells to extracellular
ATP. The concentration of extracellular ATP might be an
important determinant of the final outcome: it has been
shown that different concentrations of extracellular ATP could
have different biological effects.47 For example, 250 nM
extracellular ATP does not modulate Treg functions, whereas
at 1mM it ‘turns on’ T regulatory cells (Tregs) and stimulates
their proliferation and immunosuppressive ability in a
contact-dependent manner.47 The stimulation of Tregs by
ATP may also represent a mechanism by which tumors avoid
the immune system. In addition, it has also been shown that
under conditions that cause prolonged release of low amounts
of ATP, this nucleotide has amore subtle modulatory function,
inducing a distorted DC maturation and diminishing the
ability of mature DCs to initiate type 1 immune responses.40,48
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All these add another angle of complexity to the role of ATP in
immunogenicity.
Role of Extracellular HMGB1 in Cancer Treatment
HMGB1 is a non-histone chromatin-binding protein expressed
constitutively by all eukaryotic cells. In the nucleus it mediates
different functions, such as stabilization of nucleosomes,
DNA repair and recombination, and transcription.49 Although
the nuclear function of HMGB1 was described in 1975,50 its
extracellular immunomodulatory role was discovered only
24 years later.51 The authors found that HMGB1was secreted
as a cytokine by cultured macrophages after stimulation with
endotoxin, TNF or IL-1, and that administration of antibodies
against HMGB1 attenuated endotoxin lethality in mice.51 This
study for the first time pointed to a previously unrecognized
immunomodulatory role of HMGB1 in experimental mouse
models of sepsis and in septic patients. It is now well
established that extracellular HMGB1 participates in many
biological processes, such as angiogenesis, myogenesis,
chemotaxis and wound healing.52–59 To fulfill its functions,
extracellular HMGB1 binds to various receptors, including
TLR2, TLR4, TLR9 and the receptor for advanced glycosyla-
tion end products (RAGE).60 Further down we will analyze its
pro- and anti-tumorigenic activities and emphasize that
HMGB1 is one of the DAMPs that have dual and opposite
effects on cancer treatment. In cancer therapy, HMGB1 is a
double-edged sword (Figure 3).
HMGB1 is associated with cell injury (and acts as a DAMP).
Initially, it was proposed that HMGB1 is passively released
only from necrotic cells, whereas apoptotic and secondary
necrotic cells retain it in the nucleus.61 However, it has
become clear that most anti-cancer agents and inducers of
apoptosis and ICD can promote HMGB1 release. It has been
shown that extracellular HMGB1 is required for the immuno-
genicity of ICD.62 These authors used a prophylactic tumor
vaccination model, in which immunization of mice with
HMGB1 depletes CT26 cancer cells or co-injection of anti-
HMGB1 antibody compromises the ability of mice to resist re-
challenge with live CT26 cancer cells. An effective immune
response against cancer cells undergoing ICD requires that
DCs have functional TLR4 and intact signaling through its
adaptor MYD88 so that antigen from dying tumor cells can be
processed and cross-presented efficiently.62 Retrospective
clinical analysis confirmed these data. In breast cancer
patients, loss-of-function single-nucleotide polymorphism
(SNP; Asp299Gly) in the Tlr-4 gene (reduces binding of
HMGB-1 to TLR-4) correlated with early relapse after
anthracycline treatment.62 In addition, it was recently shown
that levels of HMGB1 increase significantly in the plasma of
breast cancer patients who respond to neoadjuvant chemo-
therapy with epirubicin/docetaxel, but not in non-respon-
ders.63 Similarly, loss-of-function SNP mutation in the Tlr-4
gene (Thr399Ile) was associated with the worst overall
survival of patients with head and neck squamous cell
carcinomas after anthracycline administration64 and of
patients with colorectal cancer receiving oxaliplatin-based
therapy.65 Also, several other studies pointed to the contribu-
tion of extracellular HMGB1 to the efficacy of anti-cancer
treatment. For example, it has been shown that HMGB-1
released from dying tumor cells treated with adenoviral vector,
radiation and temozolomide led to infiltration of DCs and to
regression of TLR-2-dependent brain tumors in a mouse
model.66 Although all these studies point to the anti-cancer
role of HMGB1, it is necessary to mention the other face of
HMGB1: its pro-tumorigenic properties.
ANTI-TUMORIGENICITY:
Activates the anti-tumor immune 
response via activation of the 
NLRP3 inflammasome and IL-1β 
production
Recruitment of antigen-
presenting cells (APCs) to sites 
of extensive apoptosis
Regulation of DC migration
PRO-TUMORIGENICITY:
Stimulates cell proliferation
Stimulates Treg proliferation and 
immunosuppressive ability
Diminishes the capacity of DCs to amplify type 
I immune responses
Stimulates migration of cancer cells
Hydrolysis of ATP to adenosine
Immune suppression
Promotes the tumor micro-environment
ATP
Figure 2 ATP is actively secreted by dying tumor cells in the early apoptotic stage and could be involved in pro- and anti-tumorigenic activities
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Several studies have indicated that HMGB1 is involved in
tumor tissue invasion and metastasis. It has been shown that
blockade of RAGE–HMGB1 decreased growth and meta-
stasis of both implanted tumors and tumors developing
spontaneously in susceptible mice.67 HMGB1 also mediates
the development of murine colitis and colitis-associated
cancer.68 The authors showed in the colitis-associated cancer
model that a neutralizing anti-HMGB1 antibody decreased
tumor incidence and size. Recently, it has been shown that the
HMGB1 released from dying cells is critical for tumor
progression in an established mouse model of prostate
cancer. In this model, HMGB1 was required for the activation
and intratumoral accumulation of T cells expressing cytokine
lymphotoxin-a1b2 (LT) on their surface.16 These tumor-
activated T cells were essential for promoting the progression
of preneoplasia to invasive carcinoma in an LTb receptor-
dependent manner.16 Extracellular HMGB1 enhances re-
growth and metastasis of cancer cells that have survived
chemotherapy.69 Another study showed that HMGB1 could
decrease anti-tumor immunity via interaction with T-cell
immunoglobulin domain and mucin domain 3 (TIM-3).20
Tumor-associated DCs in mouse tumors and cancer patients
showed strong expression of TIM-3, which interacted with
HMGB1 and in that way decreased the therapeutic efficacy of
DNA vaccination by diminishing the immunogenicity of
DAMPs (e.g. nucleic acids) released from dying cancer
cells. Moreover, the authors showed that cisplatin, a non-
immunogenic chemotherapeutic,70 might compromise the
innate anti-tumor responses of DCs by acting together with
TIM-3-dependent inhibitor pathways.20
All these various functions of HMGB1 could be partially
explained by a switching among mutually exclusive redox
states. Recent studies have found that reduced cysteines
make HMGB1 a chemoattractant, whereas a disulfide bond
makes it a proinflammatory cytokine, and further cysteine
oxidation to sulfonates mediated by ROS abrogates both
activities.4 The different redox states of HMGB1 could be
analyzed by liquid chromatography tandem mass spectro-
metric analysis and by electrophoretic mobility of HMGB1 in
the presence and in the absence of dithiothreitol.4 It has also
been shown that the redox state of extracellular HMGB1
critically regulates the autophagic response to anti-cancer
agents and thereby influences anti-tumor efficacy. Reducible
HMGB1 binds to RAGE, induces Beclin-1-dependent
autophagy, and promotes resistance to chemotherapeutic
agents or ionizing radiation, while oxidized HMGB1 increases
the cytotoxicity of these chemotherapeutics via induction of
apoptosis.71
From one point of view all these modifications could occur
after the release of HMGB1 within the injured tissues. A
possible scenario was proposed for muscle injury:4 all-thiol-
HMGB1 is released first to recruit leukocytes, which in turn
produce disulfide-HMGB1 directly by secretion and/or in-
directly by ROS-mediated partial oxidation of extracellular
HMGB1. Sustained ROS production induces the terminal
oxidation of HMGB1, which gets inactivated during the
resolution of inflammation. However, the extracellular redox
state in cancer may be highly variable.72 Different cancer cell
types or different stages of progression of the same cancer
cell type might generate unique extracellular redox states.72
ANTI-TUMORIGENICITY:
HMGB1 binds TLR-4 on dendritic 
cells, which signals via MYD88
HMGB1SH acts as chemoattractant
and recruits leukocytes
RAGE HMGB1SO H increases 
cytotoxicity of chemotherapeutics and 
irradiation by inducing apoptosis
HMGB1
PRO-TUMORIGENICITY:
RAGE HMGB1SH or S-S induces Beclin-1-
dependent autophagy and resistance to 
chemotherapeutics and irradiation
RAGE HMGB1 also induces tumor 
tissue invasion and metastasis
HMGB1 contributes to murine colitis-
associated cancer
TIM-3 HMGB1 interaction e.g. on 
dendritic cells decreases anti-tumor 
immunity
Figure 3 Passive release of HMGB1 from the nucleus of tumor cells during the late stages of apoptotis (e.g. secondary necrosis) induces both pro- and anti-tumorigenic
activities, which may depend on the redox state of HMGB1. The redox states are indicated by SH (fully reduced), S-S (disulfide bonds), SO3H (oxidized) and% (unknown)
Many faces of DAMPs in cancer therapy
O Krysko et al
5
Cell Death and Disease
This redox state variability associated with cancer cells may
partially explain the diversity of HMGB1 effects in anti-tumour
immunity.12
But from another point of view, modification of HMGB1
(and possibly of other DAMPs) could be caused by activation
of a certain biochemical pathway during a specific cell death
modality. For example, it has been shown that caspase
activity in apoptosis is responsible for modification of the
immunogenic form of HMGB1 into the non-immunogenic
oxidized HMGB1 form.73 In fact, the biochemical processes
activated during the different cell death modalities (e.g. in
apoptosis versus necroptosis) may profoundly affect
the composition and properties of the released DAMPs.74
It is also important to take into account that properties of
the intrinsic tumor microenvironment, such as the hypoxia
often present within tumors,75 could modify the action of
ICD stressors and modulate the immunomodulatory proper-
ties of DAMPs. It was recently shown that hypoxia leads to
HMGB1 release, which contributes to tumor invasiveness.76 It
is well known that hypoxic conditions lead to increased
production of ROS, which not only mediate hypoxia-induced
HMGB1 release77 but could also modify the redox state of
HMGB1. However, in these studies71,76,77 no distinction was
made between all-thiol-HMGB1 and disulfide-HMGB1. It is
important to analyze whether these three different redox
states of HMGB1 (all-thiol-HMGB1, disulfide-HMGB1
and oxidized HMGB1) can explain the different functions of
HMGB1 in anti-cancer treatment.
Future Perspectives
The insights from the last several years increasingly support
the idea that DAMPs represent one of themain characteristics
of ICD that are required to induce anti-tumor immunity. Most
studies are focusing on experimental mouse models, but it is
necessary to explore the possibility of designing large-scale
studies in order to determine the prognostic value of ICD
associated with DAMP emission in patients suffering from
different types of cancers. But it should be kept in mind
that under certain conditions, the presence of DAMPs in the
tumor microenvironment can promote tumor metastasis and
progression. The main question concerns the difference
between DAMPs that drive cancer progression and those
that inhibit tumor growth. To answer that question, it will be
essential to characterize the post-translational modifications
of DAMPs, the chemotherapeutic drugs, and the types of
tumors and their microenvironment.
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